How Does Moderna Make its Money?
Moderna is a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines. The company’s flagship product is Spikevax, the COVID-19 vaccine that generated over $36B in cumulative revenue since its 2021 launch. Moderna has since expanded to mRESVIA (RSV vaccine, approved 2024) and has a pipeline of 40+ mRNA programs spanning infectious diseases, oncology, rare diseases, and autoimmune conditions.
Moderna (MRNA) Business Model
Moderna operates in the biotechnology sector. Below is a summary of Moderna’s revenue streams, how the company generates income, and the key financial metrics from its most recent annual report. This breakdown uses data from Moderna’s 2024 fiscal year filings with the SEC.
Moderna Competitors
Moderna’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Pfizer, and Novo Nordisk. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Moderna stacks up by comparing their revenue breakdown, margins, and growth metrics.
Moderna Competitors
Moderna’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Pfizer, and Novo Nordisk. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Moderna stacks up by comparing their revenue breakdown, margins, and growth metrics.
Moderna Competitors
Moderna’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Pfizer, and Novo Nordisk. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Moderna stacks up by comparing their revenue breakdown, margins, and growth metrics.
Moderna Competitors
Moderna’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Pfizer, and Novo Nordisk. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Moderna stacks up by comparing their revenue breakdown, margins, and growth metrics.
Moderna Competitors
Moderna’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Pfizer, and Novo Nordisk. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Moderna stacks up by comparing their revenue breakdown, margins, and growth metrics.
Moderna Competitors
Moderna’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Pfizer, and Novo Nordisk. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Moderna stacks up by comparing their revenue breakdown, margins, and growth metrics.
Moderna Competitors
Moderna’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Pfizer, and Novo Nordisk. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Moderna stacks up by comparing their revenue breakdown, margins, and growth metrics.
Moderna Competitors
Moderna’s key competitors and comparable public companies in the biotechnology sector include Eli Lilly, Pfizer, and Novo Nordisk. Each of these companies competes for market share, investor attention, and revenue in overlapping segments. See how Moderna stacks up by comparing their revenue breakdown, margins, and growth metrics.
Revenue Breakdown
| Product | 2024 | 2023 | YoY Growth |
|---|---|---|---|
| Spikevax (COVID-19 Vaccine) | $3.2B | $6.7B | -52.2% |
| mRESVIA (RSV Vaccine) | $0.15B | — | New |
| Other/Grant Revenue | $0.35B | $0.3B | +16.7% |
| Total Revenue | $3.76B | $6.84B | -45.0% |
Spikevax (COVID-19) — 85% of Revenue
Moderna’s mRNA-based COVID-19 vaccine. Revenue has declined sharply from the 2022 peak of $18.4B as:
- COVID-19 vaccinations shifted from mass campaigns to annual seasonal boosters
- Competition from Pfizer/BioNTech and Novavax
- Pandemic urgency faded
The COVID vaccine is transitioning to a seasonal respiratory product (fall booster shots), similar to the annual flu vaccine market.
mRESVIA (RSV) — New Product
FDA-approved in May 2024 for adults 60+. The first mRNA-based RSV (respiratory syncytial virus) vaccine. Competes with GSK’s Arexvy and Pfizer’s Abrysvo. Revenue was modest in the first partial year but represents Moderna’s first non-COVID commercial product.
Income Statement Overview
| Metric | 2024 | 2023 |
|---|---|---|
| Total Revenue | $3.76B | $6.84B |
| Cost of Sales | $1.80B | $3.60B |
| R&D Expense | $4.75B | $4.85B |
| Operating Income | -$4.35B | -$3.60B |
| Net Income | -$3.60B | -$4.71B |
Key Financial Metrics
- Gross Margin: 52.1% — Compressed from 79% at peak as lower COVID vaccine volumes reduce manufacturing efficiency and Moderna takes inventory writedowns.
- R&D Spending: $4.75B — Moderna is spending more on R&D than it generates in revenue. The company is betting its cash reserves ($10B+) that the mRNA platform will produce multiple blockbuster products.
- Cash & Investments: $10.8B — Moderna built a massive cash stockpile from COVID revenues. This funds the pipeline through ~2028 without additional financing.
- Net Loss: -$3.6B — Operating at a significant loss as R&D spending exceeds revenue.
Is Moderna Profitable?
No, Moderna is not currently profitable on a net income basis. The company reported a net loss of $3.60B on total revenue of $3.76B. Investors watching MRNA should monitor the path to profitability closely.
What to Watch
- Pipeline execution — Moderna has 40+ mRNA programs. The most important near-term catalysts:
- mRNA-1083 (flu + COVID combo): Phase 3 results expected 2025. Could be a massive market.
- mRNA-1345 (next-gen RSV): Improved formulation
- INT-1 (individualized cancer vaccine): Personalized neoantigen vaccine with Merck for melanoma. Phase 3 underway.
- COVID seasonalization — Can Moderna maintain $3-4B+ in annual COVID vaccine revenue as a seasonal product? Pricing, market share, and booster uptake rates are key.
- Cash runway — With $10.8B in cash and ~$4B in annual cash burn, Moderna has ~3 years of runway. Pipeline successes must materialize before the cash runs out.
- Flu + COVID combination vaccine — If approved, a single-shot combo targeting both flu and COVID could capture a large share of the annual respiratory vaccine market.
- Oncology/rare disease mRNA — Personalized cancer vaccines and rare disease enzyme replacement therapies represent the long-term platform potential. Still early but scientifically groundbreaking.
Moderna (MRNA) Financial Summary
Moderna (MRNA) is a biotechnology company that generated $3.76B in total revenue in fiscal year 2024. The company reported a net loss of $3.60B, as it continues to invest in growth. For a deeper look at Moderna’s revenue breakdown, business segments, and financial performance, review the detailed analysis above.